Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD ASTRA
NCT05648448Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Feb 2023
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 2 trial of oseltamivir, favipiravir, zanamivir, baloxavir marboxil, molnupiravir in influenza, sponsored by University of Oxford. Started Feb 2023; status: recruiting.
02
Drugs
oseltamivirfavipiravirzanamivirbaloxavir marboxilmolnupiravir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05648448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648448.